Adial Pharmaceuticals Completes Azora Merger, Expands Ulcerative Colitis Pipeline

Key Takeaways

• Adial Pharmaceuticals completed the Azora Therapeutics merger on June 11, 2026
• Merger consideration includes 437,474 common shares and 12,930.617 convertible preferred shares
• Coastlands Capital led a $32 million upfront private placement with potential $32 million milestone tranche
• The deal adds AT177, a clinical-stage program for ulcerative colitis, to Adial's pipeline
• Tax-free reorganization establishes Azora as a wholly-owned subsidiary

Merger Terms and Financing

Adial Pharmaceuticals closed its tax-free reorganization with Azora Therapeutics on June 11, 2026. The merger structure makes Azora a wholly-owned subsidiary of Adial.

The merger consideration included 437,474 common shares and 12,930.617 Series A Non-Voting Convertible Preferred Stock, according to the 8-K filing. Each preferred share converts to 1,000 common shares. The company also issued pre-funded warrants for 11,780,948 shares at $2.7489 per warrant.

The financing package, led by Coastlands Capital, includes $32 million upfront with a potential $32 million milestone tranche. Additional participants include Boxer Capital Management, Stonepine Capital Management, and AuGC BioFund, according to company disclosures.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is medium for this topic. Track designations, submission types, and label or guidance shifts that could move timelines.

What It Means

The merger adds AT177, described in SEC filings as a colon-targeted aryl hydrocarbon receptor agonist being developed for ulcerative colitis. The asset represents Adial's entry into inflammatory bowel disease therapeutics.

Post-close capitalization totals approximately 28.5 million common stock equivalents, reflecting significant equity dilution from the transaction. The pre-funded warrant structure adds potential for an additional 11.7 million shares, giving investors capital-raising flexibility tied to clinical milestones.

The deal structure—split financing with a milestone-contingent second tranche—ties half the capital to AT177's development progress. According to the SEC filing, Adial plans to file an Investigational New Drug application in Q2 2027 and initiate Phase 1a trials in the first half of 2027. The milestone tranche likely triggers on one of these events, though specific terms were not disclosed.

Frequently Asked Questions

Q: When did the Adial-Azora merger close? A: The merger closed on June 11, 2026, according to the SEC 8-K filing.

Q: What financing did Adial secure? A: $32 million upfront via private placement, with a potential additional $32 million milestone tranche led by Coastlands Capital.

Q: What is AT177? A: According to SEC filings, AT177 is a colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.

Q: Who led the private placement? A: Coastlands Capital led the financing, with participation from Boxer Capital, Stonepine Capital, and AuGC BioFund.

Q: What is the tax treatment of the merger? A: The transaction was structured as a tax-free reorganization under federal tax law.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Adial Pharmaceuticals and Azora Therapeutics reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

What's Next

Adial's disclosed milestones include an IND filing for AT177 in Q2 2027 and Phase 1a trial initiation in the first half of 2027, according to the SEC filing. The $32 million milestone tranche provides capital contingent on achieving specified development targets, though the specific trigger events were not disclosed in the available filings.

Matt Davidson, PhD, former CEO of Azora Therapeutics, continues as Chief Development Officer of the combined company, providing continuity for the AT177 program.